share_log

Sera Prognostics | 10-Q: Q3 2024 Earnings Report

Sera Prognostics | 10-Q: Q3 2024 Earnings Report

Sera Prognostics | 10-Q：2024財年三季報
美股SEC公告 ·  2024/11/07 11:32

Moomoo AI 已提取核心訊息

Sera Prognostics reported Q3 2024 financial results with revenue of $29,000 and a net loss of $7.9 million, compared to $42,000 revenue and $7.2 million net loss in Q3 2023. The company ended the quarter with $74.3 million in cash, cash equivalents and marketable securities, which is expected to fund operations into 2027.The company made significant progress with its PreTRM test, announcing positive results from the AVERT PRETERM TRIAL showing an 18% reduction in severe neonatal morbidity and mortality. The PRIME study enrollment was stopped in December 2023 due to efficacy, with final database lock completed in September 2024. Top-level trial results were communicated in October 2024.Sera continues to focus on market adoption of PreTRM test through evidence generation and commercial strategy refinement. The company established a new at-the-market offering program for up to $50 million and implemented whole-blood specimen collection to enable greater market penetration. Operating expenses were $8.9 million for Q3 2024, compared to $8.2 million in Q3 2023.
Sera Prognostics reported Q3 2024 financial results with revenue of $29,000 and a net loss of $7.9 million, compared to $42,000 revenue and $7.2 million net loss in Q3 2023. The company ended the quarter with $74.3 million in cash, cash equivalents and marketable securities, which is expected to fund operations into 2027.The company made significant progress with its PreTRM test, announcing positive results from the AVERT PRETERM TRIAL showing an 18% reduction in severe neonatal morbidity and mortality. The PRIME study enrollment was stopped in December 2023 due to efficacy, with final database lock completed in September 2024. Top-level trial results were communicated in October 2024.Sera continues to focus on market adoption of PreTRM test through evidence generation and commercial strategy refinement. The company established a new at-the-market offering program for up to $50 million and implemented whole-blood specimen collection to enable greater market penetration. Operating expenses were $8.9 million for Q3 2024, compared to $8.2 million in Q3 2023.
Sera Prognostics公佈了2024年第三季度財務結果，營業收入爲29,000美元，淨虧損爲790萬元，而2023年第三季度的營業收入爲42,000美元，淨虧損爲720萬元。公司結束該季度時現金、現金等價物及可交易證券爲7430萬元，預計這將支持其運營直到2027年。公司在PreTRm測試上取得了顯著進展，宣佈了來自AVERt PRETERm TRIAL的積極結果，顯示嚴重新生兒發病率和死亡率降低了18%。由於療效，PRIME研究的招募於2023年12月停止，最終數據庫鎖定於2024年9月完成。頂級試驗結果於2024年10月公佈。Sera繼續專注於通過證據生成和商業策略優化，推動PreTRm測試的市場接受度。公司建立了一項新的市場發行計劃，最高額度爲5000萬元，並實施了全血樣本收集，以促進更大的市場滲透。2024年第三季度的營業費用爲890萬元，而2023年第三季度爲820萬元。
Sera Prognostics公佈了2024年第三季度財務結果，營業收入爲29,000美元，淨虧損爲790萬元，而2023年第三季度的營業收入爲42,000美元，淨虧損爲720萬元。公司結束該季度時現金、現金等價物及可交易證券爲7430萬元，預計這將支持其運營直到2027年。公司在PreTRm測試上取得了顯著進展，宣佈了來自AVERt PRETERm TRIAL的積極結果，顯示嚴重新生兒發病率和死亡率降低了18%。由於療效，PRIME研究的招募於2023年12月停止，最終數據庫鎖定於2024年9月完成。頂級試驗結果於2024年10月公佈。Sera繼續專注於通過證據生成和商業策略優化，推動PreTRm測試的市場接受度。公司建立了一項新的市場發行計劃，最高額度爲5000萬元，並實施了全血樣本收集，以促進更大的市場滲透。2024年第三季度的營業費用爲890萬元，而2023年第三季度爲820萬元。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Pacific Biosciences of California
    PACB
    -- 1.850
    Avita Medical
    RCEL
    -- 10.570
    PAVmed
    PAVM
    -- 0.7900
    古特拉
    CUTR
    -- 0.481
    Lifeward
    LFWD
    -- 2.185
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    科技巨頭財報季如火如荼，英偉達壓軸會表現如何？
    週四， $亞馬遜 (AMZN.US)$ 該公司報告第四季度調整後每股收益爲1.86美元，高於1.50美元的預期，營業收入爲1877.9亿美元，高於1873.2亿美元的預期。公司預測下一季度營收將低於華爾街的預期，預計本季度最多爲1550亿美元，而分析師們希望達到1580亿美元。 展开
    亞馬遜收益預覽：通過猜測開盤價格獲得獎勵！